Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 10, 2016, Pages 1904-1906

  Teusink Cross, Ashley ^a   Davies, Stella M ^b   Danziger Isakov, Lara ^a   El Bietar, Javier ^b   Grimley, Michael S ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Bone Marrow Transplantation and Immune Deficiency   (United States)

Author keywords

Bone marrow transplantation; Hematopoietic stem cell transplantation; Palivizumab; Respiratory syncytial virus; Viral prophylaxis

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; COST CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; MORBIDITY; MORTALITY; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TREATMENT OUTCOME; VIRUS INHIBITION; CLINICAL PRACTICE; DRUG EFFECTS; ECONOMICS; FEMALE; INFANT; MALE; PNEUMOVIRUS; PRACTICE GUIDELINE; PREMEDICATION; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY;

ANTIVIRAL AGENTS; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MORBIDITY; MORTALITY; PALIVIZUMAB; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREMEDICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES;

EID: 84992083960     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.07.005     Document Type: Article

References (10)

1. 1 Chemaly, R.F., Ghantoji, S.S., Shah, D.P., et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol 36 (2014), e376–e381.
2. 2 Chemaly, R.F., Shah, D.P., Boeckh, M.J., Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 59:suppl 5 (2014), S344–S351.
3. 3 Neemann, K., Freifeld, A., Respiratory syncytial virus in hematopoietic stem cell transplantation and solid-organ transplantation. Curr Infect Dis Rep, 17, 2015, 490.
4. 4 Robinson, J.L., Grenier, D., MacLusky, I., Allen, U.D., Respiratory syncytial virus infections in pediatric transplant recipients: a Canadian Paediatric Surveillance Program study. Pediatr Transplant 19 (2015), 659–662.
5. 5 Lanari, M., Vandini, S., Capretti, M.G., Lazzarotto, T., Faldella, G., Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res, 2014, 2014, 850831.
6. 6 Mori, M., Morio, T., Ito, S., et al. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome. J Infect Chemother 20 (2014), 455–459.
7. 7 El-Bietar, J., Nelson, A., Wallace, G., et al. RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant, 2016, 10.1038/bmt.2016.124.
8. 8 American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee., Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134 (2014), 415–420.
9. 9 Clark, A., Porzotrigo, M., Mathew, S., et al. Retrospective evaluation of palivizumab efficacy and safety for RSV prophylaxis in pediatric hematopoietic stem cell transplant patients: a single center experience. Biol Blood Marrow Transplant 22 (2016), 519–5481.
10. 10 Chu, H.Y., Chin, J., Pollard, J., Zerr, D.M., Englund, J.A., Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. Influenza Other Respir Viruses 10 (2016), 205–210.